
Genetic Technologies Limited GENE
Annual report 2022
added 08-30-2022
Genetic Technologies Limited DSO Ratio 2011-2026 | GENE
Annual DSO Ratio Genetic Technologies Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 11.7 K | 581 | 300 | 279 | 130 | 88.9 | 35.5 | 49 | 13.5 |
All numbers in AUD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.7 K | 13.5 | 1.47 K |
DSO Ratio of other stocks in the Diagnostics research industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Anixa Biosciences
ANIX
|
275 | $ 2.96 | 4.59 % | $ 96.1 K | ||
|
Agilent Technologies
A
|
63.8 | $ 120.24 | 1.01 % | $ 36.6 B | ||
|
Centogene N.V.
CNTG
|
145 | - | -6.23 % | $ 30.6 M | ||
|
Aspira Women's Health
AWH
|
50.7 | - | -6.19 % | $ 10.5 M | ||
|
Burning Rock Biotech Limited
BNR
|
31.7 | $ 22.65 | -3.78 % | $ 237 M | ||
|
Castle Biosciences
CSTL
|
49.2 | $ 28.41 | 3.05 % | $ 789 M | ||
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M | ||
|
Fulgent Genetics
FLGT
|
77.4 | $ 14.16 | 2.68 % | $ 428 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
90.8 | - | - | $ 562 M | ||
|
Heska Corporation
HSKA
|
40.8 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
101 | - | -20.0 % | $ 1.06 M | ||
|
Charles River Laboratories International
CRL
|
65 | $ 179.46 | 2.15 % | $ 8.89 B | ||
|
Accelerate Diagnostics
AXDX
|
291 | - | -61.36 % | $ 2.46 M | ||
|
IDEXX Laboratories
IDXX
|
43.5 | $ 647.88 | 1.94 % | $ 52.1 B | ||
|
Illumina
ILMN
|
61.3 | $ 130.02 | 0.36 % | $ 20.7 B | ||
|
Global Cord Blood Corporation
CO
|
112 | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
67.2 | - | 1.08 % | $ 308 M | ||
|
Genetron Holdings Limited
GTH
|
122 | - | 0.12 % | $ 80.1 M | ||
|
Laboratory Corporation of America Holdings
LH
|
52.9 | $ 281.34 | -0.61 % | $ 23.4 B | ||
|
Lantheus Holdings
LNTH
|
80.5 | $ 78.17 | -0.86 % | $ 5.28 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
98.1 | - | - | $ 10.7 B | ||
|
Motus GI Holdings
MOTS
|
77.2 | - | -34.28 % | $ 263 K | ||
|
Biodesix
BDSX
|
41.7 | $ 15.13 | -2.4 % | $ 1.96 B | ||
|
Mettler-Toledo International
MTD
|
66.4 | $ 1 299.93 | -1.22 % | $ 26.8 B | ||
|
Biocept
BIOC
|
112 | - | -13.05 % | $ 7.29 M | ||
|
Myriad Genetics
MYGN
|
52.3 | $ 5.36 | 1.32 % | $ 496 M | ||
|
NeoGenomics
NEO
|
77.7 | $ 9.27 | -2.83 % | $ 1.19 B | ||
|
Invitae Corporation
NVTA
|
242 | - | - | $ 21.2 M | ||
|
BioNano Genomics
BNGO
|
83.4 | $ 1.15 | 2.23 % | $ 1.46 M | ||
|
National Research Corporation
NRC
|
33 | $ 13.2 | -1.46 % | $ 324 M | ||
|
Quest Diagnostics Incorporated
DGX
|
44.9 | $ 208.35 | - | $ 23.1 B | ||
|
Danaher Corporation
DHR
|
55.3 | $ 205.14 | 0.54 % | $ 146 B | ||
|
Organovo Holdings
ONVO
|
79.8 | - | -2.3 % | $ 19.4 M | ||
|
Exact Sciences Corporation
EXAS
|
30.8 | $ 103.51 | 0.13 % | $ 19.5 B | ||
|
OPKO Health
OPK
|
240 | $ 1.2 | 0.84 % | $ 833 M | ||
|
Bioventus
BVS
|
92.3 | $ 8.57 | -1.95 % | $ 537 M | ||
|
Pacific Biosciences of California
PACB
|
71.8 | $ 1.59 | 4.28 % | $ 477 M | ||
|
DarioHealth Corp.
DRIO
|
85.8 | $ 9.51 | -7.67 % | $ 270 M | ||
|
DexCom
DXCM
|
87 | $ 73.14 | 0.08 % | $ 28.5 B | ||
|
PerkinElmer
PKI
|
92.2 | - | -0.91 % | $ 14.7 B | ||
|
Psychemedics Corporation
PMD
|
61.3 | - | -1.84 % | $ 15.3 M | ||
|
Precipio
PRPO
|
28.1 | $ 26.97 | 7.99 % | $ 35 M | ||
|
QIAGEN N.V.
QGEN
|
30.8 | - | - | $ 10.6 B | ||
|
Personalis
PSNL
|
55.8 | $ 8.84 | 1.96 % | $ 524 M | ||
|
ICON Public Limited Company
ICLR
|
68.5 | $ 110.7 | 1.84 % | $ 9.13 B | ||
|
Quotient Limited
QTNT
|
45.1 | - | -11.32 % | $ 1.1 M | ||
|
Renalytix AI plc
RNLX
|
15.9 | - | 5.66 % | $ 22.7 M | ||
|
CareDx, Inc
CDNA
|
51.5 | $ 19.3 | 2.66 % | $ 1.03 B |